Pharmafocus Home
    
Keyword Search
Go News Archive Features Events Appointments Jobs Contact Us About Us
Latest Features ( May )
Should I stay or should I go?
There are no easy answers when it comes to timing a job move, says Tim Ewbank, but you can make yourself a more attractive candidate for that next job.(more)
Regional research still hampered by cross-border differences
In the age of the Euro-trial, patients are not well served by processes that add unnecessary delays to the development of new medicines, says Les Rose(more)
A sea of paperwork or business as usual?
Steven Gray looks ahead to the soon-to-be finalised 2008 ABPI Code of Practice and how it will affect everyday practice in the UK industry(more)
PharmafocusNews Register for New Alert
News for July 2006
Previous Months: April 2008 |  March 2008 |  February 2008 |  January 2008 |  December 2007 |  November 2007 |  October 2007 |  September 2007 |  August 2007 |  July 2007 |  June 2007 |  May 2007 |  April 2007 |  March 2007 |  February 2007 |  January 2007 |  December 2006 |  November 2006 |  October 2006 |  September 2006 |  August 2006 |  July 2006 |  June 2006 |  May 2006 |  April 2006 |  March 2006 |  February 2006 |  January 2006 |  December 2005 |  November 2005 |  October 2005 |  September 2005 |  August 2005 |  July 2005 |  June 2005 |  May 2005 |  April 2005 |  March 2005 |  February 2005 |  January 2005 |  December 2004 |  November 2004 |  October 2004 |  September 2004 |  August 2004 |  July 2004 |  June 2004 |  May 2004 |  April 2004 |  March 2004 |  February 2004 |  January 2004 |  December 2003 |  November 2003 |  October 2003 |  September 2003 |  August 2003 |  July 2003 |  June 2003 |  May 2003 |  April 2003 |  March 2003 |  February 2003 |  January 2003 |  December 2002 |  November 2002 | 

  What is RSS?

Novartis speeds up Tasigna programme
Hopes that cancer drug will benefit Glivec-resistant patients..(more)

 Xeloda filed for advanced stomach cancer
Promising results and cheaper administration make drug an attractive first-line option..(more)

 UK uptake of vaccine boosts Wyeth
After a slow start, Prevnar growth gathers speed..(more)

 Patient dies after winning access to cancer drug
But PCT says it will continue to consider high-cost drug Tarceva on a case-by-case basis..(more)

 Pfizer sets out on $17 billion acquisition trail
Company optimistic about future sales despite spate of patent expiries..(more)

 Roche surges on cancer drug sales
Company's growth so far this year has been three times the industry rate..(more)

 NHS allergy services criticised
Government may commission NICE guidance after allergies cost NHS £1bn per year..(more)

 New licence allows patients to switch to Arimidex
AstraZeneca poised to exploit its cancer drug's market lead..(more)

 AstraZeneca and Abbott to develop combined lipid-targeting drug
Deal represents AstraZeneca's third major collaboration in 12 months ..(more)

 Tysabri returns with new safety precautions
Risk management plan put in place to overcome dangerous side effects..(more)

 PCT fights Herceptin approval
Cancer charity accuses Newbury PCT of using delaying tactics to save money..(more)

 MabThera approved for rheumatoid arthritis
Sales growth rate of 23% in 2005 set to increase even further..(more)

 Avastin filed for breast cancer treatment
But cost could could prove a major obstacle..(more)

 Venomous snail provides Eisai with new painkiller
Drug provides relief from chronic pain in opioid-resistant patients..(more)

 Practice-based commissioning uptake exaggerated, say GPs
BMA suggests government's claims are dishonest..(more)

 Company behind Northwick Park trial files for insolvency
Inconclusive investigation results deter investors..(more)

 Work progressing on Scotland's 'unique' biotech campus
Centre to bring together academia, clinical practice and and biomedicine..(more)

 Lilly to close UK manufacturing site but retains R&D operations
Loss of 400 jobs after cutbacks on drug development spending..(more)

 Scotland NHS appoints first private provider
But Scottish heath unions and BMA criticise the move..(more)

 J&J buys Pfizer consumer health division for $16 billion
Sale allows Pfizer to expand its prescription-only business..(more)

 Novartis to market new vaccine for Japanese encephalitis
Intercell likely to capture US military market..(more)

 New drug for treatment-resistant HIV approved
J&J's protease inhibitor offers new option for patients..(more)

 Acomplia launched in UK
Weight-loss drug also helps combat diabetes and heart disease..(more)

 New COPD standards to tackle inequalities
But British Thoracic Society says more measures must be put in place..(more)

 Generic company fails to overturn Lipitor patent in UK
Ranbaxy generic blocked until 2011..(more)

 Hepatitis B treatment Baraclude approved in Europe
Superior potency should make it a new first-line choice..(more)

Are you a Pharmafocus subscriber?

Subscribe Now 

Visit our sister sites: 

InPharm.com 

Pharmafile.com 

Pharmafocus.com © 2006 Pharmafile Ltd.